FDA approvals comprise majority of 2023 psoriasis news

Key takeaways:

• The most read story discussed the associations between cardiovascular disease, psoriasis and other inflammatory diseases.
• This year, the FDA approved Zoryve, Bimzelx and a Stelara biosimilar for psoriasis.

The FDA’s approvals of various therapeutics comprised the majority of Healio Dermatology’s most read psoriasis articles this year.

While the top read articles this year for psoriasis included a study evaluating the associations between cardiovascular disease and inflammatory skin diseases followed by a presentation about oral roflumilast, the most common theme among these articles is a large amount of FDA approvals.

Here are five of the most read psoriasis articles on Healio this year:

Cardiovascular disease associated with four dermatological inflammatory diseases

Patients with rosacea, alopecia areata, psoriasis or atopic dermatitis all face an elevated risk for cardiovascular disease, according to a study. While past literature has demonstrated an increased risk for cardiovascular disease among those with AD and psoriasis, this study found similar risks associated with rosacea and alopecia. Read more.

Oral roflumilast effective, inexpensive treatment option for patients with psoriasis

In March at the American Academy of Dermatology Annual Meeting in New Orleans, a speaker presented a study which found that oral roflumilast may offer an inexpensive and effective treatment option for patients with psoriasis who are candidates for systemic therapy. Of those treated with roflumilast, 34.8% achieved PASI 75 by week 12 compared with 0% of the placebo group. Read more.

FDA approves Zoryve for pediatric psoriasis

In October, the FDA approved a supplemental new drug application for Zoryve (roflumilast cream 0.3%, Arcutis Biotherapeutics), a nonsteroidal topical treatment previously indicated for patients aged 12 years and older. This approval expanded the indication to include children aged 6 to 11 years with psoriasis. Read more.

FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis

Also in October, the FDA approved Bimzelx (bimekizumab-bkzx, UCB) for moderate to severe plaque psoriasis treatment in adults who are eligible for systemic therapy or phototherapy, making Bimzelx the first and only interleukin 17A and 17F inhibitor approved in this indication. Read more.

FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases

The FDA approved Wezlana (ustekinumab-auub, Amgen) as a Stelara biosimilar for the treatment of plaque psoriasis, psoriatic arthritis and other inflammatory diseases in November. The approval was indicated for patients aged 6 years and older who are candidates for phototherapy or systemic therapy, as well as active psoriatic arthritis in patients aged 6 years and older. Read more.